Monitor the June 4, 2026 annual meeting vote outcome for Ms. Szela's re-election. A significant 'against' vote would signal governance concerns, but the board's proactive supplement suggests they expect close scrutiny rather than defeat. No immediate trading catalyst.
KURA drugs
KURA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 27 $10.24entry
- T+1 · 6mo ago −2.64%α −3.19% · $9.97
- T+5 · 6mo ago −15.48%α −15.95% · $8.66
- T+20 · 5mo ago +1.17%α +3.07% · $10.36
- T+60 · 3mo ago +14.36%α +12.48% · $11.71
Price Chart
How similar events traded
Executive Summary
Kura Oncology filed a DEFA14A supplement addressing overboarding concerns regarding director nominee Mary T. Szela, who serves on four public company boards. The board argues her experience and attendance record justify her re-election and notes her intention to reduce board seats before the 2027 annual meeting. The filing is routine proxy solicitation material with no financial impact.
Key Financial Metrics
Key Facts
- Supplement to the definitive proxy statement dated April 10, 2026, for the annual meeting on June 4, 2026.
- Board unanimously recommends voting FOR the election of Mary T. Szela to a three-year term expiring at the 2029 annual meeting.
- Ms. Szela serves as CEO/President of TriSalus Life Sciences and on the boards of Kura, TriSalus, Absci Corporation, and Averin Capital Acquisition Corp.
- Ms. Szela attended over 85% of Kura board/committee meetings in 2025 and over 90% since joining the board in November 2018.
- Ms. Szela has expressed intention to step down from one other public company board seat before Kura's 2027 proxy statement filing.
- All four public companies on which Ms. Szela serves are non-accelerated filers; three are life sciences companies.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- Potential negative vote from proxy advisors or institutional investors due to overboarding concerns.
- If Ms. Szela fails to reduce board commitments as promised, governance issues could resurface at the 2027 annual meeting.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-239481 |
| Document: 0001193125-26-239481-index-headers.html | 0001193125-26-239481 |
| Document: 0001193125-26-239481-index.html | 0001193125-26-239481 |
| Document: 0001193125-26-239481.txt | 0001193125-26-239481 |
Track record
29 reports on KURA
6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 14 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
- Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
- Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers